pyridoxal phosphate has been researched along with Idiopathic Parkinson Disease in 12 studies
Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).
pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antiparkinsonian drug L-dopa causes increased cellular synthesis of homocysteine and consequent hyperhomocysteinemia in rats." | 5.10 | Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. ( Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA, 2003) |
| "Pyridoxine metabolism was investigated in eight chronic levodopa-treated parkinsonian patients and in eight matched dopa-naive controls by measurement of plasma and erythrocyte pyridoxal-5-phosphate concentrations over a 24-hour period, following intravenous administration of pyridoxine." | 1.25 | Effect of chronic levodopa treatment on pyridoxine metabolism. ( Mars, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (83.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, JW | 1 |
| Selhub, J | 1 |
| Nadeau, MR | 1 |
| Thomas, CA | 1 |
| Feldman, RG | 1 |
| Wolf, PA | 1 |
| Morales, I | 1 |
| Dopico, JG | 1 |
| Sabate, M | 1 |
| Gonzalez-Hernandez, T | 1 |
| Rodriguez, M | 1 |
| Botteri, A | 1 |
| Hamfelt, A | 1 |
| Söderhjelm, L | 1 |
| Mars, H | 1 |
| Sandler, M | 1 |
| Tran, N | 1 |
| Papeschi, R | 1 |
| Molina-Negro, P | 1 |
| Sourkes, TL | 1 |
| Erba, G | 1 |
| Antón-Tay, F | 1 |
| Yahr, MD | 1 |
| Duvoisin, RC | 1 |
| Côté, L | 1 |
| Cohen, G | 1 |
| Pfeiffer, R | 1 |
| Ebadi, M | 1 |
| Kurtz, DJ | 1 |
| Kanfer, JN | 1 |
| Vogel, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease[NCT01238926] | 40 participants (Anticipated) | Interventional | 2008-05-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pyridoxal phosphate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Melatonin: effects on brain function.
Topics: Adenylyl Cyclases; Aminobutyrates; Animals; Behavior; Brain; Cerebral Cortex; Cyclic AMP; Electric S | 1974 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
2 trials available for pyridoxal phosphate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Line | 2003 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
9 other studies available for pyridoxal phosphate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Substantia nigra osmoregulation: taurine and ATP involvement.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Adenosine Triphosphate; Animals; Choline; Dose-Response Relati | 2007 |
Pyridoxal phosphate, tryptophan, and tyrosine in blood and cerebrospinal fluid in elderly patients.
Topics: Adult; Age Factors; Aged; Humans; Hydrocephalus; Middle Aged; Parkinson Disease; Pyridoxal Phosphate | 1984 |
Effect of chronic levodopa treatment on pyridoxine metabolism.
Topics: Aged; Erythrocytes; Humans; Levodopa; Middle Aged; Parkinson Disease; Plasma; Pyridoxal Phosphate; P | 1975 |
How does L-dopa work in parkinsonism?
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Blood-Brain Barrier; Dihydroxyphenylalanine; Dopa Deca | 1971 |
L-Dopa and pyridoxine.
Topics: Decarboxylation; Dihydroxyphenylalanine; Dopamine; Humans; Oxidation-Reduction; Parkinson Disease; P | 1972 |
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Cerebral Palsy; Cerebral Ventricles; Diazepam; Dihydroxyp | 1972 |
On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Benzyl Compounds; Dihydroxyphe | 1972 |
L-DOPA: effect on cerebral pyridoxal phosphate content and coenzyme activity.
Topics: Animals; Brain; Carboxy-Lyases; Cerebral Cortex; Coenzymes; Dihydroxyphenylalanine; Dopamine; Glutam | 1971 |
Non-enzymatic decarboxylation of dihydroxypheylalanine.
Topics: 5-Hydroxytryptophan; Carbon Dioxide; Carbon Isotopes; Chemical Phenomena; Chemistry; Copper; Dihydro | 1969 |